CytomX Therapeutics will release Q3 financial results on November 6, followed by a conference call.
Quiver AI Summary
CytomX Therapeutics, Inc. announced that it will release its third quarter financial results on November 6, 2025, after U.S. markets close. A conference call and webcast will follow at 5:00 p.m. ET, during which participants can access the live event via the company's website. CytomX is focused on developing innovative biologics for cancer treatment through its PROBODY® therapeutic platform, creating therapies that target the tumor microenvironment. Their clinical pipeline includes candidates like CX-2051, an ADC for certain cancers, and CX-801, a cytokine aimed at both immuno-oncology sensitive and "cold" tumors. The company has collaborations with major oncology firms such as Amgen and Bristol Myers Squibb. For more details, interested parties are encouraged to visit the CytomX website.
Potential Positives
- CytomX Therapeutics is preparing to report third quarter financial results, indicating ongoing business operations and transparency to investors.
- The upcoming conference call and webcast demonstrate the company's commitment to engaging with stakeholders and keeping them informed on financial performance.
- CytomX’s multi-modality technology platform showcases its innovative approach and potential to develop diverse therapeutics for cancer treatment.
- The establishment of strategic collaborations with major oncology leaders strengthens CytomX’s position in the market and may enhance its research and development capabilities.
Potential Negatives
- Announcement of third quarter financial results may indicate potential issues with financial performance, raising concerns among investors.
- Company's reliance on a narrow pipeline of candidates (CX-2051 and CX-801) could signal vulnerability if these products do not succeed in clinical trials.
- Dependence on collaborations with other major companies for development may suggest limitations in internal capabilities or resources.
FAQ
When will CytomX report its third quarter financial results?
CytomX Therapeutics will report its third quarter financial results on November 6, 2025, after the close of U.S. markets.
How can I access the CytomX conference call?
Participants can access the live conference call via the Events and Presentations page on CytomX’s website.
What is CytomX’s PROBODY® therapeutic platform?
The PROBODY® therapeutic platform is designed to develop localized biologics that are conditionally activated in the tumor microenvironment.
What are the main products in CytomX's clinical pipeline?
CytomX's clinical pipeline includes CX-2051 and CX-801, both designed for cancer treatment.
Who are CytomX's strategic collaborators in oncology?
CytomX has established collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CTMX Insider Trading Activity
$CTMX insiders have traded $CTMX stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $CTMX stock by insiders over the last 6 months:
- SEAN A. MCCARTHY (CEO) sold 55,511 shares for an estimated $149,263
- MARCIA BELVIN (SVP, Chief Scientific Officer) sold 13,884 shares for an estimated $37,334
- CHRISTOPHER OGDEN (Chief Financial Officer) has made 0 purchases and 2 sales selling 12,255 shares for an estimated $33,381.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CTMX Hedge Fund Activity
We have seen 62 institutional investors add shares of $CTMX stock to their portfolio, and 27 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VR ADVISER, LLC added 13,969,882 shares (+inf%) to their portfolio in Q2 2025, for an estimated $31,711,632
- FMR LLC added 9,130,557 shares (+8429.9%) to their portfolio in Q2 2025, for an estimated $20,726,364
- ORBIMED ADVISORS LLC added 8,461,500 shares (+inf%) to their portfolio in Q2 2025, for an estimated $19,207,605
- PERCEPTIVE ADVISORS LLC added 6,993,646 shares (+inf%) to their portfolio in Q2 2025, for an estimated $15,875,576
- VIVO CAPITAL, LLC added 5,769,230 shares (+inf%) to their portfolio in Q2 2025, for an estimated $13,096,152
- FRANKLIN RESOURCES INC added 5,769,230 shares (+inf%) to their portfolio in Q2 2025, for an estimated $13,096,152
- POINT72 ASSET MANAGEMENT, L.P. added 5,434,623 shares (+205.1%) to their portfolio in Q2 2025, for an estimated $12,336,594
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$CTMX Analyst Ratings
Wall Street analysts have issued reports on $CTMX in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Barclays issued a "Overweight" rating on 10/21/2025
- Cantor Fitzgerald issued a "Overweight" rating on 09/22/2025
- Oppenheimer issued a "Outperform" rating on 07/31/2025
- HC Wainwright & Co. issued a "Buy" rating on 05/20/2025
- Piper Sandler issued a "Overweight" rating on 05/15/2025
To track analyst ratings and price targets for $CTMX, check out Quiver Quantitative's $CTMX forecast page.
$CTMX Price Targets
Multiple analysts have issued price targets for $CTMX recently. We have seen 5 analysts offer price targets for $CTMX in the last 6 months, with a median target of $6.0.
Here are some recent targets:
- Etzer Darout from Barclays set a target price of $6.0 on 10/21/2025
- Olivia Brayer from Cantor Fitzgerald set a target price of $6.0 on 09/22/2025
- Matthew Biegler from Oppenheimer set a target price of $7.0 on 07/31/2025
- Mitchell Kapoor from HC Wainwright & Co. set a target price of $5.0 on 05/20/2025
- Joseph Catanzaro from Piper Sandler set a target price of $5.0 on 05/15/2025
Full Release
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report third quarter financial results on Thursday, November 6, 2025, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT.
Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX’s website at https://ir.cytomx.com/events-and-presentations . Participants may register for the conference call here and are advised to do so at least 10 minutes prior to joining the call. An archived replay of the webcast will be available on the Company’s website.
About CytomX Therapeutics, Inc.
CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated, masked biologics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY
®
therapeutic platform, CytomX’s vision is to create safer, more effective therapies for the treatment of cancer. CytomX’s multi-modality technology platform has produced therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators such as cytokines. CytomX’s current clinical-stage pipeline includes CX-2051 and CX-801. CX-2051 is a masked, conditionally activated ADC directed toward epithelial cell adhesion molecule (EpCAM), armed with a topoisomerase-1 inhibitor payload. CX-2051 has potential applicability across multiple EpCAM-expressing epithelial cancers, including CRC, and was discovered in collaboration with ImmunoGen. CX-801 is a masked interferon alpha-2b PROBODY
®
cytokine with broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CytomX has established strategic collaborations with multiple leaders in oncology, including Amgen, Astellas, Bristol Myers Squibb, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit
www.cytomx.com
and follow us on
LinkedIn
and
X
(formerly Twitter).
Company Contact:
Chris Ogden
SVP, Chief Financial Officer
[email protected]
Investor Contact:
Precision AQ (formerly Stern Investor Relations)
Stephanie Ascher
[email protected]
Media Contact:
Redhouse Communications
Teri Dahlman
[email protected]
